In this video, health care analysts David Williamson and Max Macaluso discuss Vertex's recent tie up with two deep-pocketed members of big pharma. Although Vertex currently owns the standard of care for hepatitis C treatments, it isn't sitting on its laurels. Watch and find out what this new deal means for Vertex, its partners, and its competitors.

David Williamson owns shares of Johnson & Johnson. The Motley Fool owns shares of Gilead Sciences, GlaxoSmithKline, and Johnson & Johnson. Motley Fool newsletter services recommend Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, and Vertex Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.